Cancer patients often develop the local recurrence and distant metastases of malignant tumors following radiation therapy. Escalations in the radiation dose have been used to overcome these problems; however, the dose that cancer patients can receive is limited due to side effects in the surrounding normal tissues. It is widely accepted that the combination of chemotherapeutic agents with radiation therapy, which is called chemo-radiotherapy, is a rational strategy for sensitizing cancer cells to radiation therapy and compensating for lower radiation doses.
Scientific RepoRts | 5:15666 | DOi: 10.1038/srep15666 RNF8, and the tumor suppressor p53 binding protein 1, 53BP1 by mitotic kinases 2 . Therefore, genes that are responsible for the progression of this cell cycle phase are considered to be potential targets for enhancing the therapeutic effects of radiation.
Polo-like kinase 1 (PLK1) is a serine/threonine kinase that plays important roles throughout the progression of the mitotic phase, including centrosome maturation, mitotic entry, chromosome segregation, and cytokinesis 3 . PLK1 is activated through the phosphorylation of its threonine 210 residue (T 210 ) by Aurora-A in a Bora-dependent manner 4, 5 . The active form promotes entry into the mitotic phase, e.g. by phosphorylating and activating Cdc25C 6, 7 . PLK1 was previously shown to be overexpressed in various types of cancers and is known to be responsible for the aberrant proliferation of cancer cells. Another important function of PLK1 is to control DNA damage responses through the regulation of p53 binding protein 1 (53BP1) and claspin activities 8, 9 . For example, PLK1 was reported to directly bind 53BP1 during mitosis and inactivate the DNA damage checkpoint 9 . Moreover, the intratumoral expression levels of PLK1 have been correlated with the poor prognoses of patients with various types of cancers [10] [11] [12] [13] [14] [15] [16] [17] [18] . These findings justify both the development of PLK1 inhibitors as anti-cancer agents and their application to chemoradiotherapy.
In the present study, we assessed the importance of PLK1 blockade-mediated mitotic arrest in sensitizing cancer cells to radiation therapy by using the novel small molecule inhibitor of PLK1, TAK-960 19, 20 . We herein demonstrated, for the first time, the radiosensitizing effects of TAK-960 and provided direct evidence for the involvement of mitotic arrest in the radiosensitizing effects of PLK1 blockade using the mutant type of PLK1 mimicking T210 phosphorylation.
Results
Optimal TAK-960 treatment for mitotic arrest in vitro. Accumulating evidence in the research field of radiation biology has demonstrated that the radiosensitivity of cells depends on the phases of the cell cycle; cells are relatively radioresistant in the late S-phase, but are radiosensitive in the mitotic phase (M-phase). This fundamental principle prompted us to hypothesize that the small molecule inhibitor of PLK1, TAK-960, which has been reported to cause the mitotic arrest of cancer cells 19 , may enhance the cytotoxic effects of radiation. In order to test this possibility, we first determined the optimal conditions of the TAK-960 treatment for mitotic arrest without apparent cytotoxic effects in vitro. We treated human cervical cancer cells, HeLa, with various concentrations of TAK-960 and performed cell cycle analyses using flow cytometry with propidium iodide. Among the various concentrations of TAK-960 examined, 16 nM resulted in the most pronounced cell cycle arrest at the G 2 /M phase (Fig. 1a,b ), but had a significant cytotoxic effect in the clonogenic survival assay ( Supplementary Fig. S1 online) . On the other hand, lower concentrations of TAK-960, such as 8 nM, led to G 2 /M cell cycle arrest without significant cytotoxicity. We then treated HeLa cells with 8 nM TAK-960 for various periods to optimize the duration of the treatment (Fig. 1c,d ). Flow cytometric analyses revealed that the proportion of cells in the G 2 /M phase was maximized by the TAK-960 treatment for 12 hours.
In order to monitor the influence of the TAK-960 treatment on the cell cycle status in real-time, we employed HeLa-S FUCCI cells 21 , which preferentially emit orange (monomeric Kusabira-Orange2: mKO2) and green fluorescence (monomeric Azami-Green1: mAG1) in the G 1 -phase and S/G 2 /M-phase, respectively. Time-lapse imaging confirmed that cells alternatively exhibited orange and green fluorescence in the absence of the TAK-960 treatment, and the number of round-shaped cells with green fluorescence, which represent mitotic cells, slightly increased, corresponding to proper cell cycle progression ( Fig. 1e,f ; Supplementary Video S1 online). Upon exposure to 8 nM TAK-960, the number of mitotic cells markedly increased and peaked 12-18 hours after the initiation of the TAK-960 treatment, which was consistent with the results of the flow cytometric analyses (compare Fig. 1c,d with 1e-g; Supplementary Video S2 online). Taken together, these results indicated that the optimal condition for the most pronounced cell cycle arrest at the mitotic phase was 8 nM TAK-960 for 12 hours.
Radiosensitizing effects of TAK-960 in vitro.
We performed clonogenic cell survival assays in vitro to determine whether the optimized TAK-960 treatment actually enhanced the cytotoxic effects of X-irradiation. Not only HeLa cells, but also human non-small cell lung cancer cells, H1299, and human colon cancer cells, HCT116, were subjected to the same TAK-960 treatment (8 nM TAK for 12 hours) before X-irradiation because we confirmed that the TAK-960 treatment clearly induced the mitotic arrest of H1299 and HCT116 cells (Fig. 2a-c, Supplementary Fig. S2 online) . Without the radiation treatment, the number of surviving colonies was similar between the control (0 nM) and TAK-960 treatment (8 nM) groups, which is consistent with the observations in Supplementary Fig. S1 online. On the other hand, the TAK-960 treatment significantly decreased clonogenic survival after X-irradiation. The dose of radiation required to reduce the number of surviving colonies by 90% (D 10 value) was significantly decreased by the TAK-960 treatment from 4.2 ± 0.2 to 3.4 ± 0.3 Gy in HeLa, from 7.5 ± 0.6 Gy to 5.0 ± 0.6 Gy in H1299, and from 3.7 ± 0.3 Gy to 3.0 ± 0.2 Gy in HCT116 cells ( Table 1 ). The radiation enhancement ratio of the TAK-960 treatment based on the D 10 value in HeLa cells was 1.24 ± 0.4, which was similar to that of another PLK1 inhibitor, BI2536 (1.26 ± 0.3; Supplementary Fig. S3 online) . Since TAK-960 was removed from the culture medium just before irradiation in the clonogenic cell survival assays, these results indicated that a cellular response to the TAK-960 pretreatment, possibly mitotic arrest, was required for its radiosensitizing effects. Consistent with this result, the concomitant administration of TAK-960 and X-irradiation, in which cells were exposed to the drug just before irradiation and did not have sufficient time to induce any cellular responses including cell cycle arrest, did not exhibit any radiosensitization (Fig. 2d) .
Importance of mitotic arrest in the radiosensitizing effects of TAK-960. In order to directly examine whether the radiosensitizing effects of the TAK-960 treatment were dependent on its PLK1-inhibiting activity and resultant mitotic arrest, we employed mutant forms of PLK1, which were previously reported to be less sensitive to PLK1 inhibitors, and thus, promoted M-phase progression even in the presence of the inhibitor. We constructed expression vectors for the wild-type (wt) and three mutant forms of PLK1: a phosphorylation-mimicking mutant, PLK1-T210D 22, 23 , a mutant less sensitive to PLK1 inhibitors, PLK1-R136G 24 , and a mutant with both mutations, PLK1-R136G&T210D (Fig. 3a) . Flow cytometry-based cell cycle analyses using propidium iodide revealed that the forced expression of these mutants had no effect on the cell cycle distribution of HeLa cells in the absence of the TAK-960 treatment (Fig. 3b,c) . In contrast, the TAK-960-mediated increase in the proportion of cells in the G 2 /M phase was significantly suppressed by the overexpression of PLK1-R136G&T210D, but not that of PLK1-T210D or PLK1-R136G in our experimental setting (Fig. 3b,c) . Based on these results, we employed the expression vector for PLK1-R136G&T210D and directly tested the importance of mitotic arrest in the radiosensitizing effects of the PLK1 inhibitor, TAK-960 (Fig. 3d-f) . Clonogenic cell survival assays demonstrated that the radiosensitizing effects of TAK-960 were almost completely abolished by the introduction of PLK1-R136G&T210D (compare Fig. 3f with Fig. 3d,e) . We employed paclitaxel (PTX), which is known to induce cell cycle arrest at the mitotic phase as an inhibitor of microtubular depolymerization 25 to further test the importance of mitotic arrest in TAK-960-mediated radiosensitization. The clonogenic cell survival assay demonstrated that the relative radiosensitizing effects of TAK-960 were significantly decreased after the cell cycle was synchronized at the mitotic phase by paclitaxel (Fig. 3g,h ). These results clearly showed that TAK-960 enhanced the cytotoxic effects of radiation through its own PLK1-inhibiting activity and consequent cell cycle arrest at the radiosensitive mitotic phase.
Optimal TAK-960 treatment for mitotic arrest in vivo. Prior to evaluating the radiosensitizing effects of TAK-960 in vivo, we determined the optimal TAK-960 treatment to maximize the amount of cells in mitotic arrest without influencing xenografted tumor growth in vivo. We first analyzed changes in the number of mitotic cells after the administration of TAK-960 by immunohistochemistry. Mice bearing a subcutaneous HeLa tumor xenograft were administered with various doses of TAK-960 and subjected to immunohistochemical analyses using an antibody against a marker of mitotic cells, phosphorylated histone H3 (Ser10) (pHH3(S10)). The maximal number of pHH3(S10)-positive cells was observed 24 hours after the administration of 10 or 20 mg/kg TAK-960 (Fig. 4a,b) . In order to confirm this result, we conducted an optical in vivo imaging experiment using the HeLa-S FUCCI tumor xenograft model. The use of green fluorescence as an indicator of mitotic cells was justified by immunocytochemical data in which the TAK-960 treatment significantly increased the proportion of cells that were round in shape, emitted green fluorescence, and were stained with the marker of mitotic cells, pHH3(S10) ( Supplementary Fig. S4 online; Supplementary Table S1 online). Subcutaneous HeLa-S FUCCI tumor xenografts were injected with the indicated dose of TAK-960, and green and orange fluorescence from mAG1 and mKO2, respectively, was detected by the IVIS-SPECTRUM imaging system in real-time (Fig. 4c) . In order to exclude the possibility that the intensity of fluorescence was influenced by tumor growth (increases in tumor volume over time), we calculated the ratio of the intensity of green fluorescence (mAG1) to that of red fluorescence (mKO2) as an index of mitotic cells (Fig. 4d) . The mitotic index was significantly increased and peaked 24-36 hours after the administration of 10 or 20 mg/kg TAK-960, which was consistent with the immunohistochemical data for pHH3(S10) (Fig. 4d) . We then assessed the influence of the various doses of the TAK-960 treatment on the growth of HeLa tumor xenografts. The tumor growth delay assay revealed that 10 mg/kg was the maximum dose that did not influence tumor growth and did not reduce the body weights of mice ( Supplementary Fig. S5 online; Supplementary Table  S2 online) . Collectively, the optimal conditions that caused significant cell cycle arrest at the M-phase with minimum effects on tumor growth in vivo for subsequent in vivo experiments were determined to be 24 hours after the administration of 10 mg/kg TAK-960.
Radiosensitizing effects of TAK-960 in vivo.
In order to examine whether the TAK-960 treatment in the optimized treatment regimen actually enhanced the therapeutic effects of radiation in vivo, we performed tumor growth delay assays using the subcutaneous HeLa tumor xenograft model ( Fig. 5a ; Table 2 ). Tumor xenografts were locally irradiated at a dose of 0 or 10 Gy 24 hours after the oral administration of 0 or 10 mg/kg TAK-960. We intentionally selected a relatively low dose of TAK-960 (10 mg/kg), which was confirmed to be sufficient for mitotic arrest with minimal effects on the tumor growth rate ( Fig. 4 ; Supplementary Fig. S5 online) ; therefore, tumor growth after the TAK-960 treatment alone was not significantly delayed more that with the sham treatment. Tumor growth doubling time (TGDT) after the TAK-960 treatment alone was 8.3 ± 1.6 days and was not significantly longer than that after the sham treatment (9.1 ± 1.7 days; P = 0.33). Conversely, the TAK-960 treatment significantly suppressed tumor growth when combined with IR. TGDT after the combination of radiation therapy with the TAK-960 treatment was 27.4 ± 10.0 days, and was approximately 2.0-fold longer than that after radiation therapy (14.0 ± 5.1 days; P < 0.05). The same radiosensitizing effects of TAK-960 were confirmed in another tumor xenograft model with human non-small cell lung cancer cells, H1299 ( Fig. 5c ; Table 2 ). This combination did not cause any obvious side effects (Fig. 5b,d ). Taken all together, these results demonstrated that the TAK-960 treatment exhibited radiosensitizing effects in the optimized schedule. In order to further examine the importance of mitotic arrest in the radiosensitizing effects of TAK-960 in vivo, we intentionally irradiated subcutaneous HeLa tumor xenografts just after the administration of TAK-960, and TAK-960 was not allowed to induce mitotic arrest. A delay in tumor growth was not observed even after the combination of TAK-960 with radiation ( Fig. 5e ,f; Table 3 ), which supported our conclusion that the radiosensitizing effects of TAK-960 in vivo may be attributed to mitotic arrest. 
Discussion
In the present study, we determined whether the inhibition of PLK1 enhanced the cytotoxic effects of radiation by modulating the cell cycle phase of cancer cells. The novel small molecule inhibitor of PLK1, TAK-960, was confirmed to exhibit expected radiosensitizing effects when radiation was administered because TAK-960 increased the proportion of M-phase cells. This radiosensitizing function was almost completely abrogated by the forced expression of PLK1-R136G&T210D, which functions in mitotic progression even in the presence of TAK-960, further strengthening the importance of mitotic arrest for radiosensitization. Although previous studies indirectly suggested the relevance of mitotic arrest to the radiosensitizing effects of PLK1 inhibitors [26] [27] [28] [29] [30] [31] , this is the first study to clearly demonstrate the direct involvement of mitotic arrest.
Although the present study validated the importance of mitotic arrest, we have to consider other possible mechanisms underlying the radiosensitizing effects of TAK-960. For example, Liu et al. identified PLK1 as a rational target for cancer therapy by demonstrating that PLK1 blockade induced apoptosis in cancer cells because of the inhibited ability of PLK1 to suppress the pro-apoptotic function of p53 32 . This finding indicated that the radiosensitizing effects of TAK-960 were due to p53-dependent apoptosis. Moreover, as described above, accumulating evidence has demonstrated that PLK1 functions in DNA damage responses as well through the modulation of 53BP1 and claspin activities 8, 9 , and, therefore, suggests the importance of such a function in the radiosensitizing activity of TAK-960. Further studies are needed in order to more fully understand the molecular mechanisms underlying TAK-960-mediated radiosensitization.
TAK-960 as well as other PLK1 inhibitors, such as BI2536, have been confirmed to generate polyploidy cells 19 . However, polyploidy cells were only observed when cells were treated with a higher dose of TAK-960, e.g. 60 nM or higher. Therefore, we assumed that the radiosensitizing effects of TAK-960 did not result from the generation of polyploid cells, at least in our experimental setting (TAK-960 conc. = 8nM).
Our flow cytometry-based cell cycle analyses using a series of PLK1 mutants demonstrated that TAK-960-mediated increases in the number of mitotic cells were significantly suppressed by the overexpression of PLK1-R136G&T210D, but not by that of PLK1-R136G or PLK1-T210D. In contrast, a previous study reported that a R136G mutation was adequate to suppress mitotic arrest by another PLK1 inhibitor, BI2536 24 ; however, this inhibitor was predicted to inhibit PLK1 through the same mechanism of action as TAK-960 because of their structural similarities. This discrepancy may have resulted from differences in the experimental settings. We performed every in vitro experiment without synchronizing cell cycles and simply introduced PLK1-R136G&T210D, which has the phosphorylation-mimicking mutation, T210D, in addition to R136G. On the other hand, in the previous study, PLK1-R136G-overexpressing cells were synchronized at the mitotic phase, in which the T210 residue is known to be phosphorylated. Therefore, our result is not only consistent with the previous finding, but, when taken together, indicates the importance of T210 phosphorylation in addition to the R136G mutation in the resistance of cells to PLK1 inhibitors.
The total dose of radiation is commonly fractionated in recent radiation therapies for cancer patients because fractionated radiation therapy has several advantages over single-dose radiation therapy 33 . Considering the cell cycle of cancer cells, a small dose of radiation in the first round is assumed to preferentially kill radiosensitive G 2 -and M-phase cells, but fails to damage radioresistant S-phase cells. Since the cell cycle of the surviving cells will be redistributed to subsequent phases, including the radiosensitive phases, a second round of radiation at the correct time, such as 24 hours after the first treatment, is expected to kill the fraction of surviving cells. Based on this notion, known as the redistribution of the cell cycle, PLK1 inhibitors including TAK-960 also have the ability to redistribute the cell cycle of the surviving cells to the radiosensitive M-phase with fractionated radiation therapy, resulting in radiosensitization. Moreover, PLK1 inhibitors may be particularly useful in hypo-fractionated radiation therapy, in which fractionated radiation is given at an interval of every few days, and, therefore, cannot theoretically take advantage of the redistribution of cell cycles for the enhancement of its therapeutic effect.
Radiation oncologists have recently obtained powerful tools, such as intensity-modulated radiation therapy (IMRT) 34 and stereotactic radiation therapy (SRT) 35 , which enable a higher dose of radiation to be accurately and specifically delivered to a malignant tumor. However, even the most innovative strategies have failed to achieve complete remission; tumor recurrence, distant metastasis, and/or side effects in normal tissues have often been reported following radiation therapy. Based on our result in which TAK-960 enhanced the therapeutic effects of radiation with minimal side effects, TAK-960 is expected to contribute to achieving the same or stronger therapeutic effects even when combined with a reduced dose of radiation. A decrease in the radiation dose may also reduce the incidence of side effects associated with radiation therapy. Plasmid DNA. In order to construct the plasmid pcDNA3.1/PLK1, the coding sequence of the PLK1 gene was amplified by PCR from the HeLa cDNA library using the following primers: (5′ -AAAAGCTTACCATGAGTGCTGCAGTGACTG-3′ and 5′ -AGCGGCCGCTTAGGAGGCCTTGAG ACGG-3′ ), and inserted between the HindIII-NotI sites of pcDNA3.1/myc-His C (Invitrogen Corp., Carlsbad, CA, USA). Regarding construction of the plasmids pcDNA3.1/PLK1-R136G, pcDNA3.1/ PLK1-T210D, and pcDNADNA3.1-PLK1-R136G&T210D, PCR-based site-directed mutagenesis was performed using the following primer sets: (5′ -TGCCGCCGGGGGTCTCTCCTGGAGCTGCAC-3′ and 5′ -CAGGAGAGACCCCCGGCGGCAGAGCTCC-3′ for R136G, and 5′ -AGGAAGAAGGACCT GTGTGGGACTCCTAAT-3′ and 5′ -CCCACACAGGTCCTTCTTCCTCTCCCCGTC-3′ for T210D), and the resultant DNA fragments encoding PLK1-R136G, PLK1-T210D, and PLK1-R136G&T210D were inserted between the HindIII-BamHI sites of pcDNA3.1/PLK1.
Flow cytometric analysis, Western blotting, and time-lapse imaging. HeLa cells were seeded in 6-cm dishes for flow cytometric analyses (2 × 10 5 cells/dish) or in 6-well plates for western blotting (1 × 10 5 cells/well). In the cell cycle analysis using flow cytometry, cells were fixed with ice-cold 70% ethanol, re-suspended in PBS containing both RNase A (1 mg/ml) and propidium iodide (1 mg/ml), incubated at 37 °C for 30 min, and subjected to flow cytometry (BD Bioscience, Franklin Lakes, NJ, USA), as described previously 36 . The results obtained were analyzed with DIVA software (BD Bioscience). Cell lysates prepared with CelLytic M cell lysis reagent (Sigma-Aldrich, St Louis, MO, USA) were subjected to Western blotting for the detection of PLK1 and β -actin with an anti-PLK1 mouse monoclonal antibody (1:1000; Abcam, Cambridge, UK) and anti-β -actin mouse monoclonal antibody (1:500; BioVision Research Products, Mountain View, CA, USA), respectively. In time-lapse imaging, HeLa-S FUCCI cells were seeded in glass-coated 3.5-cm dishes (5 × 10 4 cells/dish) and cultured for 12 h. Just after the addition of the indicated concentrations of TAK-960, orange (monomeric Kusabira-Orange2: mKO2) and green fluorescence (monomeric Azami-Green1: mAG1) emitted from HeLa-S FUCCI cells was observed with FLUOVIEW FV10i (Olympus, Tokyo, Japan) every 20 min for 72 h.
Clonogenic survival assay. Cells (100, 200, 700, and 2,000 HeLa cells/60-mm dish, 200, 300, 500, and 1,000 H1299 cells/60-mm dish, and 100, 200, 1,000, and 10,000 HCT116 cells/60-mm dish for 0, 2, 4, and 6 Gy, respectively) were precultured in medium containing TAK-960 for 0 (Fig. 2d ) or 12 h (Figs 2a-c and 3d-f) . These cells were then exposed to 0, 2, 4, or 6 Gy X-radiation (ACROBIO Co., Tokyo, Japan) just after replacing the culture medium to a TAK-960-free one. The cells were further cultured for 2 weeks. Surviving colonies were fixed with 70% ethanol and stained with Giemsa solution. Colonies consisting of more than 50 cells were counted as surviving colonies. The plating efficiency and surviving fraction were calculated as described previously 37 .
Transient transfection. Cells were transiently transfected with pcDNA3.1/myc-His (as an empty vector (EV)), pcDNA3.1/PLK1, pcDNA3.1/PLK1-R136G, pcDNA3.1/PLK1-T210D, or pcDNA3.1/ PLK1-R136G&T210D using the Polyfection transfection reagent (Qiagen Inc., Valencia, CA, USA) according to the manufacturer's instructions. These cells were then cultured for 48 h and subjected to each in vitro experiment.
Tumor-bearing mice, TAK-960 treatment, and radiation treatment in vivo. The suspension of HeLa cells (2 × 10 6 in 100 μ L PBS) or H1299 cells (3 × 10 6 in 100 μ L PBS) was subcutaneously inoculated into the right hind legs of 8-week-old nude mice (BALB/c nu/nu mice; SHIMIZU Laboratory Supplies Co., Ltd; Kyoto, Japan). The indicated dose of TAK-960 was orally administered to tumor-bearing mice. In the radiation treatment, tumor xenografts were locally irradiated with the indicated dose of 137 Cs γ -rays using a Gammacell 40 Exactor (MDS Nordion International Inc., Ottawa, Ontario, Canada).
Immunohistochemical analyses. HeLa tumor xenografts were surgically excised 24 h after the administration of TAK-960. The tumor xenografts were embedded in OCT compound and frozen at − 80 °C. Frozen sections were rinsed quickly in PBS, fixed in 4% paraformaldehyde for 10 min, blocked with the serum-free protein block solution (Dako, Glostrup, Denmark) for 20 min, and permeabilized with 0.2% Triton X-100 in PBS for 10 min. The sections were then treated with an anti-pHH3(S10) mouse monoclonal antibody (1:1000; Abcam, Cambridge, MA, USA). pHH3(S10) was detected with Alexa Fluor 594 goat anti-mouse IgG (1:1000; Invitrogen Corp.). The reproducibility of each staining was confirmed in at least three independent tumors and representative results are shown.
Immunocytochemical analyses. HeLa-S FUCCI cells on glass coverslips were fixed with ice-cold acetone for 2 min and permeabilized with 0.2% Triton X-100 in PBS for 10 min. After being incubated for 20 min in the serum-free protein block solution, cells were treated with an anti-pHH3(S10)-antibody (1:1000). pHH3(S10) was detected with Alexa Fluor 594 donkey anti-mouse IgG (1:1000; Invitrogen Corp.). The reproducibility of each staining was confirmed in at least three independent tumors and representative results are shown.
Optical imaging of fluorescence in tumor xenografts with HeLa-S FUCCI cells. Optical in vivo
imaging was carried out with an IVIS-SPECTRUM (Caliper). Fluorescence was acquired with the filter sets EX/535 nm and EM/580 nm for mKO2 and with EX/465 nm and EM/520 nm for mAG1. During imaging, mice were anesthetized with 2.5% isoflurane gas in the oxygen flow (1.5 L per min). Signal intensities were quantified and analyzed using Living Image 2.50-Igor Pro 4.90 software (Caliper), as described previously [38] [39] [40] .
Growth delay assay. Tumor volumes were calculated as 0.5 × length × width 2 , and compared with the initial value to calculate relative tumor volume.
Statistical analyses. The significance of differences was determined using the Student's t-test. A P value < 0.05 was considered to be significant.
Ethics of animal experiments. All animal experiments were approved by the Animal Research
Committee of Kyoto University, and performed according to guidelines governing animal care in Japan.
